Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

aliskiren hemifumarate

Known as: Aliskiren Fumarate, Bis((2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-8-methyl-2-(1-methylethyl)nonanamide) (2E)-but-2-enedioate 
An orally active nonpeptide renin inhibitor with antihypertensive activity. Aliskiren selectively binds to the S3 sub-pocket of renin, an enzyme in… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Estimating the solubility and solution thermodynamics parameters of aliskiren hemifumarate (AHF) in three different room… 
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
2011
2011
  • A. Ali
  • Therapeutics and clinical risk management
  • 2011
  • Corpus ID: 214237
Background The purpose of this study was to examine the postmarketing safety profile of aliskiren hemifumarate, a first-in-class… 
  • figure 1
  • table 1
  • table 3
  • figure 2
2009
2009
Although nicotine is generally considered to be the main compound responsible for addictive properties of tobacco, experimental… 
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2006
2006
CC chemokine ligand 11 (CCL11/eotaxin) and other CC chemokine receptor 3 (CCR3) ligands (CCL24/eotaxin-2, CCL26/eotaxin-3, CCL13… 
  • figure 2
  • figure 4
  • figure 3
  • figure 5
  • table 1
2005
2005
The pharmacologic profile of YM218, (Z)-4'-{4,4-difluoro-5-[2-oxo-2-(4-piperidinopiperidino)ethylidene]-2,3,4,5-tetrahydro-1H-1… 
2005
2005
The binding and signal transduction characteristics of YM218 ((Z)-4'-{4,4-difluoro-5-[2-oxo-2-(4-piperidinopiperidino)ethylidene… 
Highly Cited
2003
Highly Cited
2003
Background and Purpose— This study examined the interaction between 5-hydroxytryptamine1B (5-HT1B) receptors and 20… 
  • figure 2
  • figure 1
  • figure 4
  • figure 3
  • figure 5
1997
1997
We report the consequences of a 4-day treatment (b.i.d) with the 5-HT2A,2B,2C receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)-2… 
1993
1993
Chronic administration (twice a day for three days and on the morning of the fourth day) of SR 46349B (trans-4-[(3Z)3-(2… 
1976
1976
  • H. Ida
  • Arzneimittel-Forschung
  • 1976
  • Corpus ID: 38933684
3-Formylamino-4-hydroxy-a-(N-1-methyl-2-p-methoxyphenethyl-aminomethyl)-benzylalcohol hemifumarate (BD 40A) was compared with…